{"id":"W2587685665","doi":"10.1182/blood.v128.22.lba-5.lba-5","title":"Results of the Persist-2 Phase 3 Study of Pacritinib (PAC) Versus Best Available Therapy (BAT), Including Ruxolitinib (RUX), in Patients (pts) with Myelofibrosis (MF) and Platelet Counts <100,000/µl","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ruxolitinib; Medicine; Internal medicine; Population; Adverse effect; Myelofibrosis; Clinical endpoint; Randomization; Intention-to-treat analysis; Randomized controlled trial; Gastroenterology; Phases of clinical research; Clinical trial; Bone marrow","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003182589,0.001403968,0.002234814,0.0003756803,0.0004563407,0.001182637,0.0008006216,0.001414883,0.004806885],"category_scores_gemma":[0.001962789,0.0006324397,0.00221363,0.0003785574,0.0008074724,0.001467341,0.0003729481,0.00397555,0.0007443551],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008809915,"about_ca_system_score_gemma":0.001441218,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005557466,"about_ca_topic_score_gemma":0.001708578,"domain_scores_codex":[0.999168,0.0004434085,0.00006107184,0.0001274615,0.00008222913,0.0001177869],"domain_scores_gemma":[0.9982743,0.0004530177,0.0004197099,0.0001284579,0.0001139531,0.0006104566],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9260998,0.02706079,0.002875591,0.0004985307,0.001605102,0.0000963877,0.0001174829,0.001176983,0.01173854,0.0001245334,0.002072597,0.02653365],"study_design_scores_gemma":[0.5194044,0.4648971,0.01068292,0.00003360294,0.001167165,0.0001836436,0.00003835534,0.0006419639,0.001517026,0.0001618869,0.001240356,0.00003154164],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.989267,0.00269361,0.0005131008,0.0005279208,0.0001308148,0.001875392,0.002844885,0.00009732963,0.00205005],"genre_scores_gemma":[0.9884515,0.001177008,0.001268183,0.0009364866,0.0002801855,0.002226089,0.003954842,0.00003949183,0.001666198],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004806885,"threshold_uncertainty_score":0.01683134,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04798725098813239,"score_gpt":0.2931100426966477,"score_spread":0.2451227917085153,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}